Eisai Signs a Research and Option Agreement with Numab to Discover and Develop Multi-Specific Antibody Immunotherapies for Cancer
Shots:
- Numab to receive up front- research funding- success fees- milestones & royalties on sales. Eisai to get an option to acquire an exclusive license to develop and commercialize novel multi-specific antibody-based molecules developed utilizing Numab’s MATCH platform
- The focus of the agreement is to leverage Numab’s multi-specific technology to generate cancer therapies providing superior efficacy and safety as compared to benchmark immunotherapies
- Numab is utilizing its Fv-stabilizing λcap technology and MATCH platform to generate multi-specific Ab with a plug-and-play novel mechanism with superior efficacy and favorable safety profiles
Click here to read full press release/ article | Ref: Businesswire | Image: Twitter
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com